Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Trial of TAK-755 for Acute Ischemic Stroke
2025-522734-31-00Phase 2Authorised
- Sponsor
- Takeda
- Start
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of conestat alfa in ischemic stroke (2 arms), sponsored by Takeda. Primary endpoint: Symptomatic intracranial hemorrhage within 120 hours. Planned start Jul 2026; status: authorised.
02
Drugs
conestat alfa
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2025-522734-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522734-31-00.